Superworth

InfuSystem price to free cash flow INFU

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Oct 23, 2026
12.1×
10-year median
10.6×
Against its 10-year history
61st
percentile: 0 is its lowest day, 100 its highest
10-year range
3.2× to 205×
Peer median
16.7×

InfuSystem's price to free cash flow is 12.1× as of Oct 23, 2026.

That is above its ten-year median of 10.6×, close to the middle of its last ten years.

Over that time it ranged from 3.2× in Sep 2017 to 205× in Feb 2020.

The median for 10 medical instruments and supplies stocks of a similar size is 16.7×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far12.1×6.3×12.1×
20257.5×5.3×10.8×
202410.7×10.7×20.8×
202322.1×8.7×25.5×
202211.4×7.7×15.6×
202116.4×11.0×24.0×
202012.8×9.5×205×
2019150×7.2×157×
20187.1×4.1×8.8×
20174.3×3.2×7.1×
20167.7×5.7×12.0×
201564.7×54.1×66.5×
201441.8×39.3×42.8×
20134.5×4.5×5.1×
20124.2×4.0×20.0×

Against its peers

Companies in Medical - Instruments & Supplies nearest InfuSystem's size, closest first, today.

CompanyPrice to free cash flow
INFUInfuSystem12.1×
UTMDUtah Medical Products20.6×
EMBCEmbecta2.3×
PDEXPro DEX29.5×
TCMDTactile Systems Technology20.0×
MDXGMimedxn/m
MOVMovado9.8×
KEQUKewaunee Scientific8.7×
IRMDIradimed43.7×
STAAStaar Surgicaln/m
BVSBioventus13.3×
Peer median16.7×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on InfuSystem

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.